Personalized prescription of tyrosine kinase inhibitors in unresectable metastatic cholangiocarcinoma

BACKGROUND: Cholangiocarcinoma is an aggressive tumor with poor prognosis. Most of the cases are not available for surgery at the stage of the diagnosis and the best clinical practice chemotherapy results in about 12-month median survival. Several tyrosine kinase inhibitors (TKIs) are currently unde...

Descripción completa

Detalles Bibliográficos
Autores principales: Poddubskaya, Elena V., Baranova, Madina P., Allina, Daria O., Smirnov, Philipp Y., Albert, Eugene A., Kirilchev, Alexey P., Aleshin, Alexey A., Sekacheva, Marina I., Suntsova, Maria V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6127913/
https://www.ncbi.nlm.nih.gov/pubmed/30202637
http://dx.doi.org/10.1186/s40164-018-0113-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6127913/
https://www.ncbi.nlm.nih.gov/pubmed/30202637
http://dx.doi.org/10.1186/s40164-018-0113-x

Ejemplares similares